Experienced Medical Affairs professional with almost 20 years experience. Science-driven expert on the external communication of complex scientific topics.
Breast cancer research and treatment, Jan 12, 2015
Inflammatory breast cancer (IBC) is a distinct clinicopathologic entity that carries a worse prog... more Inflammatory breast cancer (IBC) is a distinct clinicopathologic entity that carries a worse prognosis relative to non-IBC breast cancer even when matched for standard biomarkers (ER/PR/HER2). The objective of this study was to identify opportunities for benefit from targeted therapy, which are not currently identifiable in the standard workup for advanced breast cancer. Comprehensive genomic profiling on 53 IBC formalin-fixed paraffin-embedded specimens (mean, 800× + coverage) using the hybrid capture-based FoundationOne assay. Academic and community oncology clinics. From a series of 2208 clinical cases of advanced/refractory invasive breast cancers, 53 cases with IBC were identified. The presence of clinically relevant genomic alterations (CRGA) in IBC and responses to targeted therapies. CRGA were defined as genomic alterations (GA) associated with on label targeted therapies and targeted therapies in mechanism-driven clinical trials. For the 44 IBCs with available biomarker dat...
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Jan 6, 2016
Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective the... more Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective therapies for advanced disease. Although an association with human papillomavirus (HPV) has been established, little is known about the molecular characterization of ASCC. A comprehensive genomic analysis of ASCC was undertaken to identify novel genomic alterations that will inform therapeutic choices for patients with advanced disease. Hybrid-capture based next generation sequencing of exons from 236 cancer-related genes and intronic regions from 19 genes commonly rearranged in cancer was performed on 70 patients with ASCC. HPV status was assessed by aligning tumor sequencing reads to HPV viral genomes. Genomic alterations were identified using an established algorithm and correlated with HPV status. Sixty one samples (87%) were HPV-positive. A mean of 3.5 genomic alterations per sample was identified. Recurrent alterations in phosphoinositol-3-kinase pathway (PI3K/AKT/mTOR) genes includin...
Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in additi... more Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COVID-19). KB109 is a novel synthetic glycan that was formulated to modulate the gut microbiome composition and metabolic output in order to increase beneficial short-chain fatty acid (SCFA) production in the gut. The K031 study is designed to evaluate the safety of KB109 and characterize its impact on the natural progression of COVID-19 in patients with mild to moderate disease. The K032 study is evaluating the effect of KB109 on the gut microbiota structure and function in this same patient population. Additionally, both studies are evaluating measures of health care utilization, quality of life (QOL), laboratory indices, biomarkers of inflammation, and serological measures of immunity in patients who received SSC alone or with KB109. Noteworthy aspects of these outpa...
11574 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare and aggressive... more 11574 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare and aggressive sarcoma. nab-Sirolimus is an albumin-bound intravenous (IV) mTOR inhibitor (mTORi) approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa. The AMPECT trial (NCT02494570) was the first prospective study in advanced malignant PEComa. In exploratory biomarker analyses, TSC1 or TSC2 alterations were associated with response. We report data from the final analysis of AMPECT patients, who were naïve to mTORi, and in patients with malignant PEComa with prior mTORi exposure treated with nab-sirolimus in an expanded access program (EAP) (NCT03817515). Methods: In AMPECT, patients with malignant PEComa naïve to mTORi received nab-sirolimus (100 mg/m2 IV days 1 and 8 of every 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was ORR by independent radiology review. Other endpoints included duration of response (DO...
Bei Gao, Norma Alonzo-Palma, Brandon Brooks, Adarsh Jose, Dinesh Barupal, Muralidharan Jagadeesan... more Bei Gao, Norma Alonzo-Palma, Brandon Brooks, Adarsh Jose, Dinesh Barupal, Muralidharan Jagadeesan, Ehsan Nobakht, Ashte Collins, Ali Ramezani, Badryah Omar, Richard L. Amdur and Dominic S. Raj Department of Medicine, University of California, San Diego, California, USA; Kaleido Biosciences, Lexington, Massachusetts, USA; Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mt Sinai, New York, New York, USA; Division of Kidney Diseases and Hypertension, George Washington University School of Medicine, Washington, DC, USA; and Department of Surgery, George Washington University School of Medicine, Washington, DC, USA
Background/objective: Glioblastoma multiforme (GBM) patients have low survival rate despite multi... more Background/objective: Glioblastoma multiforme (GBM) patients have low survival rate despite multimodality treatments with surgery, radiation and chemotherapy. Recurrent GBM fare worse (6 month’s progression-free survival - 9[percnt]), reflecting minimal benefit from salvage treatment. Here we report clinical history, molecular finding and treatment response in a patient with BRAF V 600 mutated GBM arising from a ganglioglioma. Method: H&E staining and comprehensive genomic profiling (CGP) via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center. Presentation: A 25 year old man presented to our clinic in 2013 with residual/recurrent high-grade glioma (HGG) arising from a long standing ganglioglioma. The original diagnosis of ganglioglioma was made in 1999. Patient underwent sub-total resection and monitoring. In 2013, craniotomy, resection of mass and biopsy was performed. Th...
Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in additi... more Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COVID-19). KB109 is a novel synthetic glycan that was formulated to modulate the gut microbiome composition and metabolic output in order to increase beneficial short-chain fatty acid (SCFA) production in the gut. The K031 study is designed to evaluate the safety of KB109 and characterize its impact on the natural progression of COVID-19 in patients with mild to moderate disease. The K032 study is evaluating the effect of KB109 on the gut microbiota structure and function in this same patient population. Additionally, both studies are evaluating measures of health care utilization, quality of life (QOL), laboratory indices, biomarkers of inflammation, and serological measures of immunity in patients who received SSC alone or with KB109. Noteworthy aspects of these outpa...
IntroductionIn 2020, the world experienced the beginning of the severe acute respiratory syndrome... more IntroductionIn 2020, the world experienced the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as the coronavirus disease 2019 (COVID-19) pandemic. Mounting evidence indicates that the gut microbiome plays a role in host immune response to infections and, in turn, may have an impact on the disease trajectory of SARS-CoV2 infection. However, it remains to be established whether modulation of the microbiome can impact COVID-19–related symptomatology and patient outcomes. Therefore, we conducted a study designed to modulate the microbiome evaluating the safety and physiologic effects of KB109 combined with self-supportive care (SSC) vs SSC alone in non-hospitalized patients with mild to moderate COVID-19. KB109 is a novel synthetic glycan developed to increase the production of gut microbial metabolites that support immune system homeostasis through gut microbiome modulation. Our goal was to gain a better understanding of the safety of KB109, t...
e22183 Background: Comprehensive genomic profiling is increasingly incorporated in cancer treatme... more e22183 Background: Comprehensive genomic profiling is increasingly incorporated in cancer treatment decision-making in an effort to identify druggable genomic events. FoundationOne (F1) is next-generation sequencing-based comprehensive genomic profile introduced clinically in 2012. Prior work has highlighted the ability of this approach to identify clinically relevant genomic alterations (CRGA), i.e.-changes associated with an approved agent or a mechanism-based clinical trial, in more than 80% of pts (Johnson et al. Oncologist, 2014). To describe clinician’s use of F1 in practice, we undertook an observational registry study. Methods: This is an ongoing study to characterize use of F1 in routine clinical practice. Planned duration is > 2 years with ~18 months for patient (pt) enrollment and > 1 year follow-up/pt. Pts for whom F1 was ordered, informed consent was obtained and a F1 report was issued were considered eligible for participation. Results: 496 pts from 26 sites (community 81% ) comprise the pre...
e22054 Background: Comprehensive genomic profiling (CGP) of routinely fixed tissue from pts with ... more e22054 Background: Comprehensive genomic profiling (CGP) of routinely fixed tissue from pts with advanced solid tumors can uncover tumor specific gene alterations. Foundation Medicine has developed a CLIA-certified, CAP-accredited test to simultaneously characterize all 4 classes of genomic alterations in 236 (originally 182) cancer genes. Primary study objective was to determine how often physician treatment decisions for pts with advanced cancer would be modified after reviewing results of this test. Methods: This was a prospective, single-center investigator initiated trial in pts with metastatic solid tumors. Pts with disease progression after at least one treatment regimen, determined to be likely to fail current treatment (2ndline or more) within 6 months and an expected survival of ≥ 3 months were eligible. Pts signed protocol informed consent and tumor tissue was sent for CGP. Physicians completed a questionnaire indicating their choice of next appropriate treatment for pts progressing on current ...
4142 Background: Metastatic gallbladder adenocarcinoma (GBCA) has a poor prognosis and systemic t... more 4142 Background: Metastatic gallbladder adenocarcinoma (GBCA) has a poor prognosis and systemic therapies are commonly extrapolated from those used in other gastrointestinal malignancies. In this s...
625 Background: Understanding the molecular alterations in residual, treatment-refractory HER2-po... more 625 Background: Understanding the molecular alterations in residual, treatment-refractory HER2-positive breast cancer (BC) following preoperative trastuzumab (H), lapatinib (L) or both (HL) in combination with chemotherapy may help identify patients at risk for not achieving pathologic complete responses as well as genomic alterations (GA) to target to overcome therapy resistance. Here we summarize the GA present in 21 pts’ residual BC following preoperative anti-HER2 therapy. Methods: 100 pts with stage 2/3 HER2+ BC were randomized to treatment with H vs L 1250mg vs HL (L 750-1000mg) along with preoperative 5-fluoruracil, epirubicin, cyclophosphamide followed by weekly paclitaxel (Holmes F. BMC Res Notes 6:507, 2013). Following IRB-approved informed consent, targeted NGS was performed on 21 pts’ FFPE residual disease (RD) after preoperative therapy at a CLIA-certified laboratory to characterize all classes of genomic alterations across 287 cancer-related genes. Results: 3 of 21 pts with RD were HER2-nega...
151 Background: 10 to 17% of TNBCs harbor PIK3CA mutations (TCGA Nature 490:61, 2012; Khambata-Fo... more 151 Background: 10 to 17% of TNBCs harbor PIK3CA mutations (TCGA Nature 490:61, 2012; Khambata-Ford S. ASCO 2010, abst 1056). Here we report clinical history and molecular findings for a TNBC patient with loss of mutant PIK3CA in a C-refractory metastasis that was present in her primary BC, who has had an ExRx to C. Methods: Following IRB-approved informed consent, targeted NGS was performed on the pt’s FFPE primary TNBC and on a C-refractory recurrent lung metastasis at a CLIA-certified laboratory (Foundation Medicine) to characterize all classes of genomic alterations across 287 cancer-related genes. RPPA was performed at a CLIA-certified laboratory (Theranostics Health) where immunostaining with 24 antibodies was directed against HER1/2/3 pathway proteins and AR. Results: 37 yo woman presented in 2006 with grade 3 primary TNBC, infraclavicular LNs and lung metastases at 33 weeks gestation. There was no response to preop doxorubicin/cyclophosphamide and following delivery of a hea...
Chronic kidney disease is a major public health concern that affects millions of people globally.... more Chronic kidney disease is a major public health concern that affects millions of people globally. Alterations in gut microbiota composition have been observed in patients with chronic kidney disease. Nevertheless, the correlation between the gut microbiota and disease severity has not been investigated. In this study, we performed shot-gun metagenomics sequencing and identified several taxonomic and functional signatures associated with disease severity in patients with chronic kidney disease. We noted that 19 microbial genera were significantly associated with the severity of chronic kidney disease. The butyrate-producing bacteria were reduced in patients with advanced stages of chronic kidney diseases. In addition, functional metagenomics showed that two-component systems, metabolic activity and regulation of co-factor were significantly associated with the disease severity. Our study provides valuable information for the development of microbiota-oriented therapeutic strategies f...
... 1 ALBERT H. AVILA, NORMA C. ALONZO, and BARBARA M ... 2.3. Mitogen-Induced Lymphocyte Prolife... more ... 1 ALBERT H. AVILA, NORMA C. ALONZO, and BARBARA M ... 2.3. Mitogen-Induced Lymphocyte Proliferation Rats were sacrificed by rapid decapitation, and trunk blood was collected in 50-ml polypropylene tubes containing heparin (0.1 ml) and immediately placed on ice. ...
Breast cancer research and treatment, Jan 12, 2015
Inflammatory breast cancer (IBC) is a distinct clinicopathologic entity that carries a worse prog... more Inflammatory breast cancer (IBC) is a distinct clinicopathologic entity that carries a worse prognosis relative to non-IBC breast cancer even when matched for standard biomarkers (ER/PR/HER2). The objective of this study was to identify opportunities for benefit from targeted therapy, which are not currently identifiable in the standard workup for advanced breast cancer. Comprehensive genomic profiling on 53 IBC formalin-fixed paraffin-embedded specimens (mean, 800× + coverage) using the hybrid capture-based FoundationOne assay. Academic and community oncology clinics. From a series of 2208 clinical cases of advanced/refractory invasive breast cancers, 53 cases with IBC were identified. The presence of clinically relevant genomic alterations (CRGA) in IBC and responses to targeted therapies. CRGA were defined as genomic alterations (GA) associated with on label targeted therapies and targeted therapies in mechanism-driven clinical trials. For the 44 IBCs with available biomarker dat...
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Jan 6, 2016
Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective the... more Squamous cell cancers of the anal canal (ASCC) are increasing in frequency and lack effective therapies for advanced disease. Although an association with human papillomavirus (HPV) has been established, little is known about the molecular characterization of ASCC. A comprehensive genomic analysis of ASCC was undertaken to identify novel genomic alterations that will inform therapeutic choices for patients with advanced disease. Hybrid-capture based next generation sequencing of exons from 236 cancer-related genes and intronic regions from 19 genes commonly rearranged in cancer was performed on 70 patients with ASCC. HPV status was assessed by aligning tumor sequencing reads to HPV viral genomes. Genomic alterations were identified using an established algorithm and correlated with HPV status. Sixty one samples (87%) were HPV-positive. A mean of 3.5 genomic alterations per sample was identified. Recurrent alterations in phosphoinositol-3-kinase pathway (PI3K/AKT/mTOR) genes includin...
Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in additi... more Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COVID-19). KB109 is a novel synthetic glycan that was formulated to modulate the gut microbiome composition and metabolic output in order to increase beneficial short-chain fatty acid (SCFA) production in the gut. The K031 study is designed to evaluate the safety of KB109 and characterize its impact on the natural progression of COVID-19 in patients with mild to moderate disease. The K032 study is evaluating the effect of KB109 on the gut microbiota structure and function in this same patient population. Additionally, both studies are evaluating measures of health care utilization, quality of life (QOL), laboratory indices, biomarkers of inflammation, and serological measures of immunity in patients who received SSC alone or with KB109. Noteworthy aspects of these outpa...
11574 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare and aggressive... more 11574 Background: Malignant perivascular epithelioid cell tumor (PEComa) is a rare and aggressive sarcoma. nab-Sirolimus is an albumin-bound intravenous (IV) mTOR inhibitor (mTORi) approved for the treatment of adult patients with locally advanced unresectable or metastatic malignant PEComa. The AMPECT trial (NCT02494570) was the first prospective study in advanced malignant PEComa. In exploratory biomarker analyses, TSC1 or TSC2 alterations were associated with response. We report data from the final analysis of AMPECT patients, who were naïve to mTORi, and in patients with malignant PEComa with prior mTORi exposure treated with nab-sirolimus in an expanded access program (EAP) (NCT03817515). Methods: In AMPECT, patients with malignant PEComa naïve to mTORi received nab-sirolimus (100 mg/m2 IV days 1 and 8 of every 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was ORR by independent radiology review. Other endpoints included duration of response (DO...
Bei Gao, Norma Alonzo-Palma, Brandon Brooks, Adarsh Jose, Dinesh Barupal, Muralidharan Jagadeesan... more Bei Gao, Norma Alonzo-Palma, Brandon Brooks, Adarsh Jose, Dinesh Barupal, Muralidharan Jagadeesan, Ehsan Nobakht, Ashte Collins, Ali Ramezani, Badryah Omar, Richard L. Amdur and Dominic S. Raj Department of Medicine, University of California, San Diego, California, USA; Kaleido Biosciences, Lexington, Massachusetts, USA; Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mt Sinai, New York, New York, USA; Division of Kidney Diseases and Hypertension, George Washington University School of Medicine, Washington, DC, USA; and Department of Surgery, George Washington University School of Medicine, Washington, DC, USA
Background/objective: Glioblastoma multiforme (GBM) patients have low survival rate despite multi... more Background/objective: Glioblastoma multiforme (GBM) patients have low survival rate despite multimodality treatments with surgery, radiation and chemotherapy. Recurrent GBM fare worse (6 month’s progression-free survival - 9[percnt]), reflecting minimal benefit from salvage treatment. Here we report clinical history, molecular finding and treatment response in a patient with BRAF V 600 mutated GBM arising from a ganglioglioma. Method: H&E staining and comprehensive genomic profiling (CGP) via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center. Presentation: A 25 year old man presented to our clinic in 2013 with residual/recurrent high-grade glioma (HGG) arising from a long standing ganglioglioma. The original diagnosis of ganglioglioma was made in 1999. Patient underwent sub-total resection and monitoring. In 2013, craniotomy, resection of mass and biopsy was performed. Th...
Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in additi... more Objectives These 2 parallel studies (K031 and K032) aim to evaluate the safety of KB109 in addition to supportive self-care (SSC) compared with SSC alone in outpatients with mild to moderate coronavirus disease 2019 (COVID-19). KB109 is a novel synthetic glycan that was formulated to modulate the gut microbiome composition and metabolic output in order to increase beneficial short-chain fatty acid (SCFA) production in the gut. The K031 study is designed to evaluate the safety of KB109 and characterize its impact on the natural progression of COVID-19 in patients with mild to moderate disease. The K032 study is evaluating the effect of KB109 on the gut microbiota structure and function in this same patient population. Additionally, both studies are evaluating measures of health care utilization, quality of life (QOL), laboratory indices, biomarkers of inflammation, and serological measures of immunity in patients who received SSC alone or with KB109. Noteworthy aspects of these outpa...
IntroductionIn 2020, the world experienced the beginning of the severe acute respiratory syndrome... more IntroductionIn 2020, the world experienced the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as the coronavirus disease 2019 (COVID-19) pandemic. Mounting evidence indicates that the gut microbiome plays a role in host immune response to infections and, in turn, may have an impact on the disease trajectory of SARS-CoV2 infection. However, it remains to be established whether modulation of the microbiome can impact COVID-19–related symptomatology and patient outcomes. Therefore, we conducted a study designed to modulate the microbiome evaluating the safety and physiologic effects of KB109 combined with self-supportive care (SSC) vs SSC alone in non-hospitalized patients with mild to moderate COVID-19. KB109 is a novel synthetic glycan developed to increase the production of gut microbial metabolites that support immune system homeostasis through gut microbiome modulation. Our goal was to gain a better understanding of the safety of KB109, t...
e22183 Background: Comprehensive genomic profiling is increasingly incorporated in cancer treatme... more e22183 Background: Comprehensive genomic profiling is increasingly incorporated in cancer treatment decision-making in an effort to identify druggable genomic events. FoundationOne (F1) is next-generation sequencing-based comprehensive genomic profile introduced clinically in 2012. Prior work has highlighted the ability of this approach to identify clinically relevant genomic alterations (CRGA), i.e.-changes associated with an approved agent or a mechanism-based clinical trial, in more than 80% of pts (Johnson et al. Oncologist, 2014). To describe clinician’s use of F1 in practice, we undertook an observational registry study. Methods: This is an ongoing study to characterize use of F1 in routine clinical practice. Planned duration is > 2 years with ~18 months for patient (pt) enrollment and > 1 year follow-up/pt. Pts for whom F1 was ordered, informed consent was obtained and a F1 report was issued were considered eligible for participation. Results: 496 pts from 26 sites (community 81% ) comprise the pre...
e22054 Background: Comprehensive genomic profiling (CGP) of routinely fixed tissue from pts with ... more e22054 Background: Comprehensive genomic profiling (CGP) of routinely fixed tissue from pts with advanced solid tumors can uncover tumor specific gene alterations. Foundation Medicine has developed a CLIA-certified, CAP-accredited test to simultaneously characterize all 4 classes of genomic alterations in 236 (originally 182) cancer genes. Primary study objective was to determine how often physician treatment decisions for pts with advanced cancer would be modified after reviewing results of this test. Methods: This was a prospective, single-center investigator initiated trial in pts with metastatic solid tumors. Pts with disease progression after at least one treatment regimen, determined to be likely to fail current treatment (2ndline or more) within 6 months and an expected survival of ≥ 3 months were eligible. Pts signed protocol informed consent and tumor tissue was sent for CGP. Physicians completed a questionnaire indicating their choice of next appropriate treatment for pts progressing on current ...
4142 Background: Metastatic gallbladder adenocarcinoma (GBCA) has a poor prognosis and systemic t... more 4142 Background: Metastatic gallbladder adenocarcinoma (GBCA) has a poor prognosis and systemic therapies are commonly extrapolated from those used in other gastrointestinal malignancies. In this s...
625 Background: Understanding the molecular alterations in residual, treatment-refractory HER2-po... more 625 Background: Understanding the molecular alterations in residual, treatment-refractory HER2-positive breast cancer (BC) following preoperative trastuzumab (H), lapatinib (L) or both (HL) in combination with chemotherapy may help identify patients at risk for not achieving pathologic complete responses as well as genomic alterations (GA) to target to overcome therapy resistance. Here we summarize the GA present in 21 pts’ residual BC following preoperative anti-HER2 therapy. Methods: 100 pts with stage 2/3 HER2+ BC were randomized to treatment with H vs L 1250mg vs HL (L 750-1000mg) along with preoperative 5-fluoruracil, epirubicin, cyclophosphamide followed by weekly paclitaxel (Holmes F. BMC Res Notes 6:507, 2013). Following IRB-approved informed consent, targeted NGS was performed on 21 pts’ FFPE residual disease (RD) after preoperative therapy at a CLIA-certified laboratory to characterize all classes of genomic alterations across 287 cancer-related genes. Results: 3 of 21 pts with RD were HER2-nega...
151 Background: 10 to 17% of TNBCs harbor PIK3CA mutations (TCGA Nature 490:61, 2012; Khambata-Fo... more 151 Background: 10 to 17% of TNBCs harbor PIK3CA mutations (TCGA Nature 490:61, 2012; Khambata-Ford S. ASCO 2010, abst 1056). Here we report clinical history and molecular findings for a TNBC patient with loss of mutant PIK3CA in a C-refractory metastasis that was present in her primary BC, who has had an ExRx to C. Methods: Following IRB-approved informed consent, targeted NGS was performed on the pt’s FFPE primary TNBC and on a C-refractory recurrent lung metastasis at a CLIA-certified laboratory (Foundation Medicine) to characterize all classes of genomic alterations across 287 cancer-related genes. RPPA was performed at a CLIA-certified laboratory (Theranostics Health) where immunostaining with 24 antibodies was directed against HER1/2/3 pathway proteins and AR. Results: 37 yo woman presented in 2006 with grade 3 primary TNBC, infraclavicular LNs and lung metastases at 33 weeks gestation. There was no response to preop doxorubicin/cyclophosphamide and following delivery of a hea...
Chronic kidney disease is a major public health concern that affects millions of people globally.... more Chronic kidney disease is a major public health concern that affects millions of people globally. Alterations in gut microbiota composition have been observed in patients with chronic kidney disease. Nevertheless, the correlation between the gut microbiota and disease severity has not been investigated. In this study, we performed shot-gun metagenomics sequencing and identified several taxonomic and functional signatures associated with disease severity in patients with chronic kidney disease. We noted that 19 microbial genera were significantly associated with the severity of chronic kidney disease. The butyrate-producing bacteria were reduced in patients with advanced stages of chronic kidney diseases. In addition, functional metagenomics showed that two-component systems, metabolic activity and regulation of co-factor were significantly associated with the disease severity. Our study provides valuable information for the development of microbiota-oriented therapeutic strategies f...
... 1 ALBERT H. AVILA, NORMA C. ALONZO, and BARBARA M ... 2.3. Mitogen-Induced Lymphocyte Prolife... more ... 1 ALBERT H. AVILA, NORMA C. ALONZO, and BARBARA M ... 2.3. Mitogen-Induced Lymphocyte Proliferation Rats were sacrificed by rapid decapitation, and trunk blood was collected in 50-ml polypropylene tubes containing heparin (0.1 ml) and immediately placed on ice. ...
Uploads
Papers by Norma Palma